|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: YAE1D1 |
Gene summary for YAE1D1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | YAE1D1 | Gene ID | 57002 |
| Gene name | YAE1 maturation factor of ABCE1 | |
| Gene Alias | C7orf36 | |
| Cytomap | 7p14.1 | |
| Gene Type | protein-coding | GO ID | GO:0006807 | UniProtAcc | Q9NRH1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57002 | YAE1D1 | P1T-E | Human | Esophagus | ESCC | 2.84e-06 | 3.06e-01 | 0.0875 |
| 57002 | YAE1D1 | P2T-E | Human | Esophagus | ESCC | 1.44e-29 | 4.53e-01 | 0.1177 |
| 57002 | YAE1D1 | P4T-E | Human | Esophagus | ESCC | 4.78e-28 | 5.18e-01 | 0.1323 |
| 57002 | YAE1D1 | P5T-E | Human | Esophagus | ESCC | 1.35e-08 | 1.39e-01 | 0.1327 |
| 57002 | YAE1D1 | P8T-E | Human | Esophagus | ESCC | 3.19e-25 | 3.38e-01 | 0.0889 |
| 57002 | YAE1D1 | P9T-E | Human | Esophagus | ESCC | 1.24e-14 | 3.20e-01 | 0.1131 |
| 57002 | YAE1D1 | P10T-E | Human | Esophagus | ESCC | 2.91e-24 | 3.37e-01 | 0.116 |
| 57002 | YAE1D1 | P11T-E | Human | Esophagus | ESCC | 7.21e-11 | 4.11e-01 | 0.1426 |
| 57002 | YAE1D1 | P12T-E | Human | Esophagus | ESCC | 1.09e-18 | 3.89e-01 | 0.1122 |
| 57002 | YAE1D1 | P15T-E | Human | Esophagus | ESCC | 2.54e-22 | 3.87e-01 | 0.1149 |
| 57002 | YAE1D1 | P16T-E | Human | Esophagus | ESCC | 4.45e-22 | 3.67e-01 | 0.1153 |
| 57002 | YAE1D1 | P17T-E | Human | Esophagus | ESCC | 6.58e-10 | 4.14e-01 | 0.1278 |
| 57002 | YAE1D1 | P19T-E | Human | Esophagus | ESCC | 1.18e-08 | 3.92e-01 | 0.1662 |
| 57002 | YAE1D1 | P20T-E | Human | Esophagus | ESCC | 4.50e-12 | 2.20e-01 | 0.1124 |
| 57002 | YAE1D1 | P21T-E | Human | Esophagus | ESCC | 3.11e-19 | 3.25e-01 | 0.1617 |
| 57002 | YAE1D1 | P22T-E | Human | Esophagus | ESCC | 1.13e-34 | 4.82e-01 | 0.1236 |
| 57002 | YAE1D1 | P23T-E | Human | Esophagus | ESCC | 2.34e-19 | 3.89e-01 | 0.108 |
| 57002 | YAE1D1 | P24T-E | Human | Esophagus | ESCC | 6.17e-19 | 2.76e-01 | 0.1287 |
| 57002 | YAE1D1 | P26T-E | Human | Esophagus | ESCC | 7.61e-12 | 2.77e-01 | 0.1276 |
| 57002 | YAE1D1 | P27T-E | Human | Esophagus | ESCC | 9.25e-18 | 3.30e-01 | 0.1055 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| YAE1D1 | SNV | Missense_Mutation | c.445G>C | p.Glu149Gln | p.E149Q | Q9NRH1 | protein_coding | tolerated(0.29) | benign(0.006) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| YAE1D1 | SNV | Missense_Mutation | c.534N>G | p.Ile178Met | p.I178M | Q9NRH1 | protein_coding | tolerated(0.24) | benign(0.001) | TCGA-AP-A0LT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| YAE1D1 | SNV | Missense_Mutation | rs767689486 | c.227N>G | p.Tyr76Cys | p.Y76C | Q9NRH1 | protein_coding | tolerated(0.12) | probably_damaging(1) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| YAE1D1 | SNV | Missense_Mutation | rs767147083 | c.524N>G | p.His175Arg | p.H175R | Q9NRH1 | protein_coding | tolerated(0.54) | benign(0.001) | TCGA-FI-A2F9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| YAE1D1 | SNV | Missense_Mutation | c.233N>T | p.Arg78Leu | p.R78L | Q9NRH1 | protein_coding | tolerated(0.1) | benign(0.001) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| YAE1D1 | SNV | Missense_Mutation | rs773458006 | c.76N>A | p.Glu26Lys | p.E26K | Q9NRH1 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| YAE1D1 | SNV | Missense_Mutation | novel | c.146N>C | p.Gly49Ala | p.G49A | Q9NRH1 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-73-4658-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| YAE1D1 | SNV | Missense_Mutation | c.130N>A | p.Glu44Lys | p.E44K | Q9NRH1 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-78-7149-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| YAE1D1 | SNV | Missense_Mutation | rs749934423 | c.416N>T | p.Asp139Val | p.D139V | Q9NRH1 | protein_coding | deleterious(0) | benign(0.422) | TCGA-22-4593-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| YAE1D1 | SNV | Missense_Mutation | novel | c.526N>T | p.Ser176Cys | p.S176C | Q9NRH1 | protein_coding | deleterious(0.03) | benign(0.43) | TCGA-39-5034-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |